Company: SXTPW
Filing Date: 2025-03-27
Form Type: S-1/A
Source: 0001013762-25-003353
Chunk: 48

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: S-1/A
Chunk 48
---
ized under terms that are       
 more economically attractive than ours;                                                          |

| ● | collaborators                                                                                   
 may not properly maintain or defend our intellectual property rights or may use our proprietary 
 information in such a way as to invite litigation that could jeopardize or invalidate our       
 proprietary information or expose us to potential litigation;                                   |

27

| ● | collaborators                                                                                 
 may not comply with regulatory requirements and as a result their operations may be disrupted 
 or ended until they resolve their regulatory issues with government officials;                |

| ● | disputes                                                                                      
 may arise between the collaborators and us that result in the delay or termination of the     
 research, development or commercialization of our product candidates or that result in costly 
 litigation or arbitration that diverts management attention and resources;                    |

| ● | collaborations                                                                              
 may be terminated and, if terminated, may result in a need for additional capital to pursue 
 further development or commercialization of the applicable product candidates;              |

| ● | collaborators                                                                                 
 may elect to take over manufacturing rather than retain us as manufacturers and may encounter 
 problems in starting up or gaining approval for their manufacturing facility and so be unable 
 to continue development of product candidates;                                                |

| ● | we                                                                                                
 may be required to undertake the expenditure of substantial operational, financial and management 
 resources in connection with any collaboration;                                                   |

| ● | we                                                                                         
 may be required to issue equity securities to collaborators that would dilute our existing 
 stockholders’ percentage ownership;                                                        |

| ● | we                                                                      
 may be required to assume substantial actual or contingent liabilities; |

| ● | collaborators                                                                                  
 may not commit adequate resources to the marketing and distribution of our product candidates, 
 limiting our potential revenues from these products; and                                       |

| ● | collaborators                          
 may experience financial difficulties. |

We face a number of challenges in seeking additional collaborations. Collaborations are complex and any potential discussions may not result in a definitive agreement for many reasons. For example, whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator’s evaluation of a number of factors, such as the design or results of our clinical trials, the potential market for our product candidates, the costs and complexities of manufacturing and delivering our product candidates to patients, the potential of competing products, the existence of uncertainty with respect to ownership or the coverage of our intellectual property, and industry and market conditions generally. If we were to determine that